#Switzerland #Cerbios-Pharma #HAS Healthcare #65 Equity Partners #Biasca

Major Acquisition in the Pharmaceutical Industry

HAS Healthcare Advanced Synthesis SA, a prominent player in the development and production of pharmaceutical active ingredients, has officially acquired Cerbios-Pharma SA. This strategic move aims to forge an internationally leading entity in the Contract Development and Manufacturing Organization (CDMO) sector. The merger is notably backed by 65 Equity Partners, a global investment firm dedicated to fostering growth and innovation among family-owned businesses and entrepreneurs.

A New Chapter in Pharmaceutical Manufacturing

This acquisition comes at a pivotal time for both companies, allowing for the integration of their manufacturing strengths, chemical and biological expertise and technological capabilities. By collaborating, HAS and Cerbios plan to enhance their production efficiency, thereby creating new avenues for growth and solidifying their position in the international marketplace.

“It’s a significant milestone in our strategy for global expansion,” stated Riccardo Braglia, CEO of HAS, expressing enthusiasm about the opportunities this merger presents. “Together, we are poised to achieve new heights and reinforce our dedication to delivering high-quality solutions to our clients.”

Strengthening the Swiss Pharmaceutical Landscape

Located in Biasca, Switzerland, both HAS and Cerbios have established themselves as leaders in the pharmaceutical manufacturing landscape. This merger signifies a substantial enhancement in capabilities for both organizations, especially in the realm of developing complex pharmaceutical therapies, including highly potent active pharmaceutical ingredients (HPAPIs) and antibody-drug conjugates (ADCs).

With Cameroonian regulatory approvals pending, the fusion of HAS and Cerbios not only aims to streamline production processes but also emphasizes adhering to a strong corporate culture built on family ownership values and a commitment to the local Swiss region, Ticino.

Commitment to Innovation and Growth

As part of the strategic partnership, 65 Equity Partners will hold about 40% ownership alongside the Braglia family, retaining majority control. This investment underscores the intent to nurture long-term growth and innovate within the pharmaceutical sector, meeting the ever-evolving demands of global markets. “We are invigorated to join forces with the Braglia family and merge two highly compatible teams that craft solutions for many admired pharmaceutical companies,” mentioned Pascal Heberling, Partner at 65 Equity Partners.

The demand for advanced therapies, personalizations in drug development, and ongoing scientific advancements signal a robust future for both HAS and Cerbios. This merger is also projected to bolster the prestigious reputation of Ticino’s chemical-pharmaceutical industry on a global scale.

Shared Vision for Future Success

The newly formed group draws upon nearly five decades of experience, with Cerbios bringing its expertise in manufacturing generic APIs and offering CDMO services. This combination is expected to heighten the organizations’ competitive edge and foster innovation in various therapeutic areas such as oncology, neurology, and more.

“Our collaboration harnesses a workforce of over 400 employees, who are committed to driving growth and innovation,” remarked Waldo Mossi, CEO of HAS. “The union is more than just a business transaction; it’s a commitment to elevating our services quality and creating value for our clients and stakeholders.”

The Path Ahead

Looking ahead, both corporations are excited about the prospects stemming from this merger. The continued investment in technology and the enhancement of service quality will be paramount as they strive to meet the complexities of the pharmaceutical industry.

In conclusion, the acquisition marks a significant step for HAS Healthcare Advanced Synthesis SA and Cerbios-Pharma SA to accelerate growth, innovate solutions, and ultimately maintain a stronghold in the global pharmaceutical manufacturing arena. The emphasis on joint ventures and retaining foundational values promises a bright and prosperous future for the newly enlarged group.